Exponential Biotherapies

Exponential Biotherapies, Inc. devel­ops ther­a­peu­tics to atten­u­ate over­re­ac­tions of the immune sys­tem that may lead to severe organ dam­age and death.

The company’s lead prod­uct tar­gets acute renal fail­ure fol­low­ing surgery, an impor­tant cause of death in hos­pi­tal inten­sive care units.

Portfolio: MedSciences Capital B.V.

Current prod­uct devel­op­ment stage: phase II clin­i­cal tri­als.